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ABSTRACT 
The methylation profiles generated during the early stages of mouse brain development 
play a critical role in the gene expression regulation program; given the large number of 
different cellular population in murine brain, is the great importance the study of the 
cell to cell heterogeneity in terms of DNA methylation. In this work, I performed an in-
depth single molecule methylation analysis in order to assess the cell to cell 
methylation heterogeneity analyzing the epialleles composition at the D-aspartate 
oxidase (ddo) putative regulatory region, that is a gene implicated in a correct 
neurodevelopment and that undergoes a strong methylation changes during the early 
stages of mouse development. I found that brain methylation heterogeneity is generated 
and develops in an extremely conserved fashion, giving rise to a deterministically 
regulated distribution of different epialleles, distinct for each stage and cell type, 
evoking the possible existence of a novel, cell population based, combinatorial code of 
CpG methylation. Importantly, rapid epialleles remodeling toward mature neuronal and 
glial patterns was observed in ES cells population upon neural differentiation. The high 
degree of epipolimorphism, detected also in pure cell populations, supports the 
existence of mechanisms oriented to maintain the epiallele patterns in a dynamic 
equilibrium involving continuously occurring methylation and demethylation events in 
each single cell. The interplay between contiguous CpGs differing in methylation 
susceptibility likely underlies specific epiallele frequency and dynamics in a spatial-
specific manner. The present data on Ddo gene provide a proof of principle that 
employment of high coverage single molecule methylation analysis, may potentially 
reveal unprecedented mechanisms underlying methylation establishment, changes and 
alterations within cell populations in development and diseases, unpredictable by 
classical methylation analyses.  
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ABBREVIATIONS 
Ddo:  D-aspartate oxidase  
CpG:  C--phosphate--G  
ncRNA: Non coding RNA 
siRNA: Small interfering RNA 
piRNA:  RNA Piwi-interacting 
miRNA: microRNA 
lncRNA: Long non coding RNA 
DNA:  Deoxyribonucliec Acid 
DNMT: DNA methyltransferase  
RNA:  Ribonucleic acid 
TET:   Ten-eleven translocation 
PCR:  Polymerase Chain Reaction 
MSP:  Methyl Specific PCR 
NGS:  Next generation sequencing  
Ct:  Threshold cycle  
WGBS: Whole genome bisulfite sequencing  
RRBS:  Reduced representation bisulfite sequencing 
BDNF IV: Brain-derived neurotrophic factor 
CDKL5: Cyclin-dependent kinase-like 5 
MeCP2 : Methyl CpG binding protein 2 
Dlx5:  Distal-less homeobox 5 
FXYD1: FXYD domain containing ion transport regulator 1 
FOX G1: Forkhead box protein G1  
HIPP:  Hippocampus 
CX:  Cortex 
PFC:  Prefrontal cortex  
CB:  Cerebellum 
ST:  Striatum   
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INTRODUCTION 
 
1.1 Epigenetic mechanism. 
 
The story of Biology teaches us that during the development of mammals, nothing is 
left to the case, especially the gene expression. Among the main players of gene 
regulation, surely there are the epigenetic mechanisms (1). Epigenetics is the branch of 
the science that studies the heritable modifications not involving DNA nucleotide 
sequence (2) (Fig.1); three different kind of regulation subtend epigenetic changes: 
chromatin modifications (3, 4), noncoding RNA (5, 6), and DNA methylation (7). For 
what concern the chromatin epigenetics, the most common modifications are those 
borne by histone lysines (acetylation and methylation) (8). These modifications are the 
most important system to regulate the tissue-specific gene expression patterns and 
global gene silencing (9). After the fertilization, one of the main roles of histone 
methylation is to keep the differences or the asymmetry between paternal and maternal 
genomes. The maternal genome is more abundant in Lysine methylation, as H3K9me2-
3, H3K27, H3K4me3 (10, 11) than the paternal. The paternal one is characterized by 
the H4 hyperacetylation and H3K9me1 (12, 13). Instead, the second class of 
epigenetics area encloses the non-coding RNA (ncRNA); they are functional RNA 
molecules that are transcribed from DNA but not translated into proteins. They include 
siRNA, piRNA, miRNA, and lncRNA. It’s well known that the short and long 
noncoding RNA are implicated in heterochromatin formation, DNA methylation 
targeting, gene silencing and histone modification (14-20). Last but not least, the DNA 
methylation is one of the most complicated mechanisms that subtends the regulation of 
gene expression especially during the brain development of mammals (21, 22). The 
critical role of DNA methylation in neurodevelopment of mammals brain is highlighted 
by the absence of methyl-CpG binding protein 2 (MECP2), a reader of DNA 
methylation status. Indeed, its absence or mutation during the early stage of 
development may generate a strong cognitive deficit in the human brain (23, 24). So, as 
the methyl CpG readers are very important in human development, the enzymes 
involved in DNA methylation generation and maintenance are definitely among the 
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principal actors that play a crucial role in brain development. Moreover, the DNA 
methylation processes are implicated in many brain function as learning (25), memory 
formation and maintenance (26) and neuronal plasticity (27). Furthermore, It has been 
demonstrated that the alterations of DNA methylation patterns are also implicated in 
neurodegenerative and neuropsychiatric disease (28-32), highlighting the importance of 
correct formation and preservation of DNA methylation patterns in brain cells. 
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Figure 1. The root layer is the DNA sequence containing covalent modifications such as cytosine 
methylation (5mC) and hydroxymethylcytosine (5hmC). The black structure is an unmodified cytosine 
base. The DNA is then wrapped around octameric histone proteins into nucleosomes and into chromatin. 
The nucleosomal histones H2A, H2B, H3 and H4 form pairs with one H3–H4 tetramer and two H2A–
H2B dimers and can be exchanged with variants or chemically modified on their protruding tails such as 
histone 3–lysine 27 trimethylation (H3K27me3). The structure of the chromatin is mediated by the 
nucleosome packing with open/euchromatin having fewer nucleosomes positioned than 
closed/heterochromatin. The condensed heterochromatin has been shown to possess a unique solenoid 
structure and higher-order loops and folds also exist to further compact the chromatin into chromosomes. 
The various layers and modifications establish whether the gene and the regulatory components 
(promoter, enhancer) are accessible and transcribed or inactive. (From Aguilar et al. Nature Ref: 93) 
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1.2 The DNA methylation 
 
The cell-specific gene expression is a process that is finely regulated by epigenetic 
mechanisms. The ways in which this may happen are still unclear, but it’s known that 
the DNA methylation plays a key role in these processes. For this reason, during the 
last years, the modalities of generation and maintenance of DNA methylation have been 
the most central topic in the epigenetic field. As know, the functions of DNA 
methylation include the gene regulation, genomic stability and chromatin structure (33). 
Its role in prokaryotic systems is to defend the host DNA from restriction enzyme 
digestion (34), while in mammalian cells and not only, the functions of DNA 
methylation include, in addition to the gene regulation, X inactivation(35-36), genomic 
imprinting (37), DNA mismatch repair (38) and DNA replication (39). Most of these 
processes are due to methylation of cytosine base present in the CpG dinucleotide, and 
the enzymes that perform this activity are defined as the family of DNMT protein. 
There are two classes of DNMTs: de novo and maintenance DNMTs. The de novo 
DNA methyltransferases DNMT3A and DNMT3B are implicated in cytosine 
methylation of unmethylated CpG sites (40), while DNMT1 is related to the 
maintenance of the DNA methylation pattern during DNA replication (41). Using a 
restriction endonuclease accessibility assays in isolated cell nuclei it was possible to 
demonstrate the presence of the DNA methylation (42). The evidence obtained from 
this experiment suggested the existence of specific proteins that may able to binding the 
methylated CpGs. Indeed, after few years, the family of Methyl Binding Protein was 
discovered. The most studied protein of this family is MeCP2, a protein capable of 
recognizing single methyl-CpG dinucleotides (43), considered one most important 
protein implicated in a correct mammals brain development. Indeed, altered sequence 
or amount of MeCP2 protein in the brain (due to sequence mutations), is related to 
severe neurological disorders (44). Others relevant methylation modification on 
cytosine no paired with a guanosine CT, CC, CA, were also found; they are called non-
CpG methylation (45). The non CpG methylation could play a crucial role in brain 
development, indeed, their levels are high in embryonic stem (ES) but are largely lost 
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upon cell differentiation (46, 47). Moreover, the mCH levels are nearly absent in fetal 
cortex, vice versa they are copious in the adult frontal cortex (48). The mCH functions 
could be related to expression regulation as suggested by findings that in mammalian 
brain these modifications are depleted in expressed genes, with genic mCH level 
inversely proportional to the abundance of the associated transcripts (49). Moreover, 
the cytosine, in the context of CpG dinucleotides, can be found in a different 
modification status, that include the carboxi-, formyl- and hydroximethylated ones. 
These intermediate forms are produced by TET enzymes family (50, 51). These 
cytosine modifications could be part of an active DNA demethylation pathway (52). In 
brain, hydroximethylcytosine seems to be more abundant in neurons, rather than glial 
cells, and, although its role is still unclear, it was shown to be essential to obtain a 
correct brain development (48). Thus, the continuous flow of methylation and 
demethylation processes is likely essential for the correct development of mammals 
brain and only at the end of this modelling process, each type of brain cells will acquire 
a cell type-specific methylation profile becoming able to regulate the exact gene 
expression program. Indeed, the differences of epigenetic features between glia and 
neuron cells could be one of the principles that characterize the neural diversity (53). 
 
 
1.3 How to study the DNA methylation in NEXT GENERATION SEQUENCING age 
 
Methods to investigate DNA methylation are multiple, it is possible to divide into three 
main categories: i) techniques based on bisulphite conversion (54), ii) based on 
digestion performed by restriction enzymes that are sensible to the methylation CpG 
status of and iii) based on the immunoprecipitation of the methyl group. The gold 
standard method to investigate the DNA methylation status is the bisulfite DNA 
conversion followed by different kind of analyses. Using this method the unmethylated 
cytosine (C) is converted into uracil residues (U) while methylated cytosines remain 
unmodified (54). After this treatment, the detection of DNA methylation can be 
achieved by PCR (55), sanger sequencing (56), microarray (57) or next generation 
sequencing (58). The MSP (methylation specific PCR) is based on the use of two 
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couple of primers, one able to identify the unmethylated CpGs and the other one 
amplifies the methylated DNA (59). The methylation status of the analyzed region can 
be evaluated comparing the Ct derived from two Real time PCR reactions (one for each 
couple of primers, methylated or unmethylated). The classical Sanger sequencing 
involves the analysis of cloned PCR products: the bisulfite DNA is first amplified by 
specific primers, amplified fragments are cloned and then about 20-30 clones are 
subject to sequence analysis (60). The evolution of sequencing techniques, which 
improved the resolution of bisulfite analysis, was the pyrosequencing which is used to 
obtain a more quantitative DNA methylation information, and allows to detect even 
small differences in methylation average (61). Chip-arrays, specific for bisulfite treated 
genomic DNA, may include a large number of selected CpGs (typically half a million), 
and may produce an overview of genome-wide methylation status (62). Recently, the 
advent of the sequencer of latest generation has redefined the study of DNA 
methylation. The whole genome bisulfite sequencing (WGBS) produces an enormous 
amount of methylation data than ever before (63). The use of sequencer as Roche 454 
or Illumina Hiseq, allows to analyze the methylation status of the entire genome, 
making the bisulfite process followed by NGS the best technique to study the DNA 
methylation in different fields as tumor progression (64), neurodegenerative diseases 
(65), development (66) and many more. All these methods to evaluate the DNA 
methylation are able to obtain an accurate average methylation, some of these even all 
along the genome. However, the main limitation is the low coverage that do not allow 
to detect and measure cell to cell heterogeneity within a given cell population. among 
the different cell populations. In the next paragraph I will describe a novel approach, 
which includes an ultra-deep methylation analysis followed by an ad hoc generated 
bioinformatics-analysis, that was developed in my lab to overcome these limitations 
and was applied to the study of epiallele generation and evolution in brain cells during 
development and neural differentiation. 
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1.4 Cell to Cell heterogeneity and the epialleles analysis. 
 
Epigenetic profiles are sculpted during development and, in particular, DNA 
methylation landscape of mammalian brain cells is dynamically reconfigured through 
development (27, 48, 67). Such reconfiguration occurs, at brain specific genes, 
prevalently during the late stages of embryogenesis and early post-natal developmental 
period leading to critical changes in the gene expression program that, once the process 
come to end, is thought to be maintained throughout the life. A progressive shaping of 
DNA methylation patterns occurs in a regulated manner, both at CpG and CpH sites, 
mainly in a specific time-window around the birth possibly providing an epigenetic 
memory specific for each type of brain cells (48). Such phenomenon, crucial to 
complete embryonic development, is the result of a dynamic interplay between DNA 
methylation and demethylation events assisted by different DNA methyltransferases or 
by Ten-eleven translocation enzymes. At genomic level, as a result of these processes, 
each type of brain cells, despite sharing similar global mCpG content, acquire a cell-
type specific genomic DNA methylation landscape that gives an identity card for 
different brain cells and govern and stabilize an elected gene expression program. 
Indeed, in a recent comprehensive study using a novel cell separation approach, Mo et 
al. (53) found that glial cells and three different subtypes of neocortical neurons show 
very distinctive epigenomic signatures including CpG and CpH methylation state at 
promoters and intragenic regions which associate with gene specific activity, and 
concluded that epigenomic landscape reflect neuronal diversity. Appropriate patterns of 
DNA methylation in the brain play an important role in mental health (29, 68). Several 
pivotal gene-specific or genome-wide studies addressing alteration of DNA methylation 
in animal models or post-mortem brain of psychiatric subjects, nicely revealed the 
association of altered average CpG methylation at certain genes with specific 
psychiatric condition (28, 30, 69-71) or negative stressors (32, 72) confirming the 
importance of correct formation and preservation of DNA methylation patterns for 
brain functions and the role of altered configuration of brain DNA methylation profiles 
in the pathogenesis of psychiatric disorders. The vast majority of these studies, 
regardless of the techniques employed, took into consideration the average amount of 
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CpGs methylation in specific genomic regions or their genome-wide distribution with a 
only relatively high resolution. However, mammalian genome contains about 29 
million of CpG sites which are non-randomly distributed along the genome. Because 
each of CpG sites may exist in a methylated or unmethylated state, the number of 
possible combinations is huge (108,700,000) and may therefore enormously increase the 
potential information content of genomic DNA, without considering here the further 
increase provided by other cytosine modifications such as hydroxymethylation and non 
CpG methylation. Although at genomic level it is practically impossible, or at least a 
very hard task, to verify all the possible mCpG combinations present in brain cells, in 
principle each cell may bear a specific combination of methylated CpG at specific loci 
that may reflect the origin of the cell and/or the functional state of a given gene (allele) 
in that cell. This introduce the concept of “epipolymorphism” which goes far beyond 
the simple identification of differentially methylated regions, by means that brain cells 
may be considered a population of epigenetically heterogeneous cells in which each 
combination of mCpG at a given locus represents a specific epiallele. Such information 
is lost when the average methylation, even at single CpG sites, is evaluated. 
Nevertheless, although only a low number of molecules/locus (about ten to fifty) is 
usually analyzed both in gene-specific and genome-wide studies, most of previous 
studies based on bisulfite sequencing revealed that different combinations of mCpG are 
indeed present at given loci. These are usually interpreted as the effect of stochastic 
methylation and demethylation events resulting in an average methylation degree which 
is then associated to gene activity. However, it should be taken into consideration that 
each of the detected profile corresponds to the configuration of a single allele, in single 
cells belonging to the cell mixture present in an analyzed tissue. By genome-wide 
approaches, recent works, based on comparing the methylation of few adjacent CpGs, 
have addressed the heterogeneous methylation accounting for cell to cell methylation 
variability in liver (73), in leukemias (74) and in immortalized fibroblasts (75) nicely 
describe the stochastic and clonal evolution of epialleles during carcinogenesis.  
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AIM OF THESIS. 
2.1  
It is known that the balance between DNA methylation and demethylation events are 
important phenomena that influence the correct development of the mammalian brain. 
It is also known that the epigenetic mechanisms are heavily implicated in the generation 
and progression of neuropsychiatric and neurodegenerative disorders. However, little it 
is known about the cell-to cell heterogeneity of methylation profiles and how much this 
phenomenon occur in a stochastic or a well-orchestrated fashion. During my Ph.D. 
course, I investigated, by very high coverage methylation analyses, if a cell to cell 
methylation variability exists in brain and whether this variability represents the result 
of stochastic events or a genetically and/or environmentally driven phenomenon, 
developmentally regulated, leading to an orchestrated distribution of epialleles among 
the entire population of brain cells. In order to gain a proof-of-principle that precise 
analysis of variable frequencies of multiple patterns (epialleles) may help to answer 
these questions, I chose to perform an ultra-deep methylation analysis (coverage 
200.000-300.000 reads/sample) of a single locus. I found that brain epi-polymorphisms 
are generated and develop in an extremely conserved fashion giving rise to a 
deterministically regulated distribution of different epialleles, evoking the possible 
existence of a novel combinatorial code of CpG methylation within cell populations. 
The finding of highly conserved epigenetic diversity, retained in purified cell 
populations, supports the possible existence of mechanisms oriented to maintain the 
epigenetic system in a dynamic stability. My results encourage the employment of this 
novel approach to study DNA methylation since it may potentially give important 
information on cell identity and origin, functional state of a given gene and on the 
mechanisms underlying DNA methylation establishment, changes and, potentially, 
alterations of these processes in diseases.   
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MATERIAL AND METHODS 
3.1 Collection of mouse brain tissue. 
 
In my study, all brain tissues were collected from C57BL/6J (bought from Jackson 
Laboratory; Bar Harbour, ME).The mice were grown in the CE.IN.GE’s laboratories as 
in Punzo et.al (76). All research involving animals was performed in accordance with 
the European directive 86/609/EEC governing animal welfare and protection, which is 
acknowledged by the Italian Legislative Decree no. 116 (January 27, 1992). Animal 
research protocols were also reviewed and consented by a local animal care committee. 
I used half brain from each of 3 mice from different developmental stages: Embryonal 
day 15 (E15), Post Natal day 1 (P0), P15, P30, and P60. To study the methylation 
profile among the different brain areas, I collected 5 brain areas from two mice at P30 
Stage (prefrontal cortex, cortex, hippocampus, cerebellum, and striatum). All tissue 
samples were pulverized in liquid nitrogen and stored at -80°C before use. 
 
 
3.2 Cell isolation and its treatments. 
 
Primary Cortical Neurons. Cortical neurons were prepared from brains of 17-day-old 
C57BL/6J mouse embryos, as previously described (77). Briefly, mice were first 
anesthetized and then killed by cervical dislocation to minimize the animals‘ pain and 
distress. Dissection and dissociation were performed in Ca2/Mg2-free buffer saline 
(HBSS). Tissues were incubated with trypsin for 20 min at 37°C and dissociated by 
trituration in culture medium. Cells were plated at 3.5-5 x 106 in 60 mm plastic Petri 
dishes, precoated with poly-D-lysine (20 mg/ml), in MEM/F12 (Invitrogen, Carlsbad, 
CA) containing glucose, 5% deactivated FBS, and 5% horse serum (Invitrogen), 
glutamine, and antibiotics. Ara-C (10 mM) was added within 48 h of plating to prevent 
non-neuronal cell growth. Neurons were cultured at 37°C in a humidified 5% CO2 
atmosphere. All the experiments on primary cortical neurons were performed according 
to the procedures described in experimental protocols approved by the Ethical 
Committee of the Federico II University of Naples. 
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Primary microglia, oligodendrocytes, and astrocytes isolation from mixed glial cell 
cultures. 
Purified microglia, oligodendrocyte, and astrocyte cells were prepared from primary 
mouse mixed glial cells as previously described (78, 79). Briefly, cerebral cortices 
isolated from post-natal day 1 mouse brain were first dissociated enzymatically in a 
solution containing 0.125% trypsin and 1.5 mg/mL DNase (Sigma-Aldrich, St. Louis, 
MO) and then mechanically in Dulbecco‘s modified Eagle‘s medium supplemented 
with 10% fetal bovine serum, 1% penicillin-streptomycin, 2 mmol/L L-glutamine 
(Invitrogen). The cell pellet was resuspended and plated in tissue culture flasks in a 
normal medium at 37°C in a humidified, 5% CO2 incubator. After 12-15 days, the 
microglia cells were separated by a mechanical shaking of flasks on an orbital shaker 
for 60 min at 200 rpm at 37°C. The suspension containing microglia was centrifuged at 
1000 rpm for 5 min and the pellet stored at -80°C. This procedure yielded 98% IB4- 
FITC or OX42-positive cells. To isolate oligodendrocyte lineage cells, the cultures 
were then subjected to an additional 16 h of shaking at 200 rpm. To minimize 
contamination by microglial cells, the suspension of detached cells was incubated twice 
for 40 minutes at room temperature. The non-adhering oligodendrocytes were 
centrifuged at 1000 rpm for 5 min and the pellet stored at -80°C. This procedure 
yielded 98% NG2-positive cells. Finally, the remaining confluent astrocytes were 
washed, scraped, centrifuged, and the pellets stored at -80°C until further analysis. This 
procedure yielded 98% GFAP -positive cells. 
Embryonic stem cells. In vitro differentiation toward neurons and glia cells was 
performed as previously described (80). Briefly, at day 0, wild type TBV (129/SvP) 
ESCs were dissociated into a single-cell suspension and 1000 cells/cm2 were plated on 
gelatin-coated plates. The culture medium was replaced daily during the differentiation 
process. 
Immortalized cells. A1 mes c-myc (A1) is a cell line immortalized by means of 
infection with a c-myc carrying retroviral vector of a primary mouse mesencephalon 
derived cells culture prepared from 11-day-old embryos (E11) as previously described 
(81). These cells proliferate and remain undifferentiated when grown in MEM/F12 
(Invitrogen, Milan, Italy) supplemented with 10% FBS (HyClone, Milan, Italy). 
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3.3 DNA and RNA extraction protocols. 
 
DNA was extracted from a portion of liquid nitrogen–pulverized tissue or cell pellets. 
DNA was prepared using DNeasy® Blood & Tissue Kit (Qiagen, Hilden, Germany), 
following the manufacturer‘s instructions. Total mRNAs were extracted using TRI 
REAGENT® (Invitrogen) solution, according to the manufacturer׳s instructions. DNA 
and RNA were quality checked by 260/280 absorbance ratio using NanoDrop 2000, 
(Thermo Scientific) and were quantified using respectively Qubit® 2.0 Fluorometer 
with the dsDNA broad range assay kit (Invitrogen, Q32850) and Nanodrop 2000 
(RNA). 
 
3.4 cDNA and Real Time experiments. 
One microgram of total mRNA of each sample was reverse transcribed with the 
QuantiTect Reverse Transcription kit (Qiagen) using an optimized blend of oligo-dT 
and random primers, according to the manufacturer’s instructions. All Relative 
Quantitative PCR were performed using ROCHE 480 instrument in 96-well plates. To 
calculate the relative expression levels I used the 2 -DDCT method and all genes were 
normalized with GAPDH expression levels.  
 
3.5 Bisulfite treatment 
 
Bisulfite treatment was performed using EZ DNA Methylation Kit (Zymo Research). 
Genomic DNA (2 µg) was converted with ―C/T conversion reagentǁ and eluted in 50 
µl of H2O following the manufacturer‘s instruction. To estimate the rate of bisulfite 
conversion, I used a spike-in control prepared by adding fully unmethylated M13mp18 
double strand DNA (New England BioLabs) in 10 representative samples. After the 
library sequencing, I evaluated the conversion bisulfite of my experiments around 98-
99%, 
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3.6 Amplicon Library preparation 
 
To study the DNA methylation average and the epialleles distribution among different 
samples, I developed a double steps PCR strategy to generate a high quality of bisulfite 
amplicon library (Fig. 2). After the bisulfite treatment the DNA undergoes the first step 
of PCR reaction, I used a couple of tiled primers to generate products ranging in size 
from 300-450 bp. Table 1 shows all primers sequences used in this project. These 
primers contain an overhang adapter sequences at each 5’end (FW: 5‘ 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG ‗3; RV: 5‘ 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG ‗3) that must be recognized 
in the second step of PCR. The first PCR conditions are: one cycle at 95°C for 2 min 
followed by 32 cycles at 95°C for 30 s, [primer Tm] for 40 s, 72°C for 50 s, followed 
by a final extension step at 72°C for 6 min. Reactions were performed in 30 µl total 
volumes: 3 µl 10x reaction buffer, 0.6 µl of 10 mM dNTP mix, 0.9 µl of 5 µM forward 
and reverse primers, 3.6 µl MgCl2 25 mM, 2-4 µl bisulfite template DNA, 0.25 µl 
FastStart Taq, and H2O up to a final volume of 30 µl. For both PCR steps, I used the 
FastStart High Fidelity PCR System (Roche). During this first part, there is a risk to 
produce a primers dimer, because each primer is long around 60 base. To avoid this 
formation, I performed an AMPure purification leveraging the magnetic Beads 
(Beckman-Coulter, Brea, CA). These magnetic beads are positively charged and are 
therefore capable of binding DNA if you use the right concentration. I prefer to use a 
ratio AMPure Beads/PCR products volume of 0.8 in order to delete as much as possible 
the dimers. After this first purification step, I checked each product size on 1.5% 
agarose gel. Then, I make the second step of PCR, to add multiplexing indices and 
Illumina sequencing adapters. The condition of second PCR step were as follows: 50 µl 
total volume, 5 µl 10x reaction buffer, 1 µl dNTP mix, 5 µl forward and reverse Nextera 
XT primers (Illumina, San Diego, CA), 6 µl 25 mM MgCl2, 5 µl of first PCR product, 
0.4 µl FastStart Taq, and H2O up to a final volume of 50 µl. Thermocycler settings 
were: one cycle at 95°C for 2 min followed by 8 cycles at 95°C 30 s, 55°C for 40 s, 
72°C for 40 s, followed by a final extension step at 72°C for 5 min. As before, I 
repeated one AMPure Beads purification this time with a different ratio 1.2 Beads/PCR. 
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The quantification process and the check of amplicon quality were performed 
respectively using Qubit® 2.0 Fluorometer and Agilent 2100 Bioanalyzer DNA 1000 
Kit (Agilent Technologies, Santa Clara, CA), according to the manufacturer‘s 
instructions. The last step, it was the pooling of all PCR amplicons at an equimolar 
ratio. The amplicon library undergoes dilution to a final concentration of 8 picomolar. I 
decided to use a Phix control libraries (Illumina) [15% (v/v)] to increase the diversity of 
base calling during sequencing. According to the Illumina protocols, I sequenced all 
different amplicon library with a V3 reagents kits on Illumina MiSeq system (Illumina, 
San Diego, CA). Paired-end sequencing was carried out in 281 cycles per read (281 x 
2). An average of 210,000 reads/sample were used for further analysis. 
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Figure 2. The scheme of strategy preparation of a amplicon methylation library. 
 
Table 1.  
GENE AMPLICON FW PRIMER RV PRIMER 
Ddo R1 -2170/-1960 tttggtttttattTtTaaatTTtgata AactAActatacatctcacttccctA 
 Ddo R2 -1578/-1184 ggttagtggtttTtttgTagTTtttat AAcattAtcccttcaAtccacaat 
Ddo R3 -927/-499 gTttttTTaTatgtTttggagTTt acctccctAaaaAtcatttAattcta 
Ddo R4 -468/-63 gtgtgtttTtgaggaggtgaTaTtTa 
262 3 
aActtaccctccattAAtccatAcc 
Ddo R5 -229/+144 ggTtggtggTaagTtgaagttTttg acccctaaaatcccaAaAtAcatac 
Ddo R6 +267/+671 TTtagtgttaaTttattagagTtgtgg AAtacaatcccttcttAcaacaAAca 
Ddo R7 +801/+1201 gagggagttgggTatggagTaTaTata AactctaAAAaAcaAacacaAaAAtc 
M13 mp18 5946 / 6294 ggtgaagggtaattagttgttgtt ccaataccaaacttacatacct 
The capital letters in the primers sequences indicate the original C or G, respectively 
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3.7 Sequences handling 
 
The Illumina Miseq sequencer platform produces two FASTQ files for each sample, 
one file contains the sequences from forward primer and one file with sequences from 
reverse primers. The first step to analyze the obtained sequences was evaluate the 
quality of each “read” using the FASTQC programme. Then in order to acquire one 
unique FASTQ file, I used a PEAR tool (82) by selecting a minimum range of 
overlapping residues of 40 and like a quality threshold a mean PHREAD score of at 
least. The file used to analyze the results was a FASTA file, and to transform FASTQ 
into FASTA, I used a PRINSEQ tool (83). The methylation status of each CpGs was 
checked by a pipeline software (Amplimethprofiler) that I developed in collaboration 
with a group of bioinformatics from my department. The pipeline is freely available at 
https://sourceforge.net/projects/amplimethprofiler (84). This tool is specifically 
designed for deep targeted bisulfite amplicon sequencing of multiple genomic regions 
and provides functions to demultiplex, filter and extract methylation profiles directly 
from FASTA files. In my analysis, all kind of filters were taken into account (read 
length, percentage of similarity between the end of the read and the primer sequence, 
bisulfite efficiency, maximum percentage of ambiguously aligned CG sites, percentage 
of aligned read). Using these filters, all reads that didn’t match with expected length 
have been rejected. I used BLAST software (85) to aligned all reads to bisulphite 
reference of each gene in the analysis. As output, the pipeline returns: i) a summary and 
quality statistics file, containing information about the number of reads that pass 
filtering, the methylation percentage of each C in CpG sites, and the bisulfite efficiency 
for each C in non-CpG sites; ii) an alignment file where the bisulfite efficiency/read is 
calculated; iii) a CpG methylation profiles file, containing a matrix that reports the 
methylation status for each CpG dinucleotide: 0 if the site is recognized as 
unmethylated, 1 if the site is recognized as methylated, and 2 if the methylation state 
could not be assessed. Each row of the matrix can be considered as the CpG 
methylation profile and defines an epiallele in subsequent analyses. Then, we used this 
output to perform downstream analyses. Quantitative methylation averages for each site 
are then computed as the number of non-converted bases mapped on that site over the 
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total number of mapped reads. Single molecule CpG methylation arrangement was then 
performed. Based on R software (R Core Team, 2016, https://www.R-project.org), the 
abundance of each one of the 2NCpG distinct epialleles (where NCpG stands for the 
number of CpG sites in the analyzed region) was evaluated for each sample by counting 
the number of passing filter reads containing that epiallele. The filter was set in order to 
include only reads with the expected length and containing no more that 2% 
unconverted cytosine outside CpG sites.  
 
 
3.8 Statistical analysis 
 
In order to obtain a statistical significance for my data, I decided to use statistical tests 
suitable for each experiment. All statistical analyses were performed using JMP 
software ( SAS, Cary, NC). Every time I showed a methylation average data, I 
expressed the results as means ± standard deviation. In all figure, the comparisons 
between 2 groups were performed using the unpaired Student t test, while for multiple 
comparisons were made by 1-way ANOVA followed by Tukey post-hoc test. For all 
average methylation data, a P-value ≤ 0.05 was considered statistically significant. For 
what concern the statistical analysis of epialleles results, I decided to correlate the 
epialleles distribution within each stages group using a Pearson correlation test. For this 
kind of analysis, a P-value ≤ 0.001 was considered statistically significant. A principal 
component analysis (PCA) was performed on the abundance of each 64 epialleles 
presents in the analyzed cell population. PC1 explained 31.2% and PC2 explained 29% 
of the observed variance. Beta diversity indicates the differences in epialleles 
assortment among groups and it assessed using “ brain curtis distances”; this analysis is 
shown by principal coordinate analysis (PCoA) biplot that includes the impact of the 64 
epialleles driving the samples clustering. 
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RESULTS 
4.1 Candidate Gene 
 
Using the latest technique in the field of sequencing, allowed me to study in a deep 
view the DNA methylation status of certain genes, I tried to better understand the 
mechanism underling the methylation generation. I used an innovative study, the 
epialleles approach, that allow to analyze the DNA methylation from a new point of 
view. To make the most of this technique, initially, I needed to find some strong 
changes in methylation average between different mice groups, in this way I was able 
to well define individual methylation profiles. First of all, I analyzed a large number of 
genes, that are involved in a correct development of mouse brain. Given the growing 
evidence of a strong correlation between mRNA levels and the methylation status of 
gene promoters, I decide to analyze the expression of genes involved in a brain 
development during the first days of embryonic growing and the firsts two months of 
life. In Figure 3A are shown the mRNA expression of some candidate genes, BDNF 
IV, CDKL5, Mecp2, Dlx5, FXYD1, DDO, FOX G1. As shown, the majority of these 
genes changes the expression levels during the early stages of mouse brain 
development. So, I proceeded to analyze the methylation status of the promoter of these 
genes. In Figure 3B are shown the methylation average for each gene, at different step 
point. The previous two figures highlight that there weren’t correlations between 
methylation and expression for all genes. Among these, what appeared to be an increase 
in levels of expression in inverse proportion to the levels of methylation was Ddo. The 
increase of mRNA expression of this gene correspond to a strong demethylation of his 
promoter (30%) during early stages of development. This robust variation ( the best of 
my analyzed genes), is the most important reason why I decided to use the Ddo as gene 
model for my studies. 
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Figure 3. Candidate genes. A) The expression levels of BDNFIV, CDKL5, FXYD1, DDO, Mecp2, 
FOXG1, DLX5 genes. All experiments are normalized on the expression level of GAPDH. B) Average 
of methylation of the possible candidate genes. 
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4.2 Epialleles analysis principles  
 
Amplicon bisulfite sequencing of a given genomic region enables us to determine 
whether each included CpG dinucleotide, in each single molecule, is methylated or 
unmethylated. Upon high-coverage bisulfite sequencing, it is possible to determine, 
with high precision, either the average methylation at each CpG site or the asset of 
methylated and unmethylated CpG sites present in each amplicon-derived sequence. As 
an example, a region that includes 4 CpG sites may give origin to 16 possible 
combinations that may be potentially found in a mixed population of cells (Fig. 4). 
These different combinations will be here referred to as epiallele; the number of 
different exhibited epialleles provides a measure of the level of epipolymorphism (see 
Figure 4 for details and examples). I applied this kind of methylation analysis to 
investigate the epiallele combinations and evolution of the Ddo gene, as example of a 
locus undergoing methylation changes during brain development. 
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Figure 4. Principle of epipolymorphism and epiallele analysis. Averaged methylation degree, even at 
single base resolution, does not give any information on cell-to-cell methylation variability. In the 
example reported in the Figure, which shows analysis of 4 adjacent CpG sites, 50% methylation degree 
may correspond to completely different methylation scenarios. These range from the lowest degree of 
epipolymorphism (bottom left) to the highest level (bottom right). However, reliable analysis of the 
relative frequency of each epiallele must rely on a high number of analyzed sequences. Compared to 
genomic approaches previously used to measure the general epipolymorphism degree, the here adopted 
amplicon bisulfite sequencing, although limited to targeted genomic regions, allowed us to magnify the 
details of cell-to-cell epiallele variability at single loci, thanks of the very high sequencing coverage 
(about 210,000 in this study) and to comprehensively establish the methylation pattern of several 
adjacent CpG sites of longer regions (up to 600–1000 bp) in which all CpGs within individual reads are 
effectively phased and may represent the epigenetic haplotype. TSS: transcription start site. The pie 
charts represent the percentage of fully unmethylated epialleles (U = white), fully methylated epialleles 
(F = black), and the 14 remaining possible methyl CpG combination or intermediate epialleles (I = gray 
gradient). (From Florio et al 2017 Ref. 94) 
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4.3 Epialleles frequency distribution of Ddo during early stages of mouse brain 
development. 
 
D-aspartate oxidase (ddo) is a FAD-containing enzyme that selectively deaminates 
bicarboxylic D-amino acids, such as D-aspartate (D-Asp), NMDA, and D-glutamate 
(86). In the Punzo et al. paper (76), were published the results about the mRNA 
expression and DNA demethylation average of Ddo during the early stages of mouse 
brain development. As said before, in my study I decided to deepen the generation of 
these DNA methylation variations, looking from another point of view, the epialleles 
analysis. First of all, I investigated 3kb of the promoter region of Ddo (3 mice for each 
stage, E15, P0, P30) in whole brain. The promoter of this gene (Fig. 5A) is poor in a 
number of CpGs and as shown in figure 5B the demethylation process that affected the 
region around TSS, is not common to all regions and to all CpGs. The first three 
regions (R1-R3) that aren’t subject to a change in methylation average, while the R6 
and R7 seem to undergo the same demethylation process of the regions R4 and R5, 
except for some CpGs. Then, I proceeded to do an epiallele analysis of all promoter 
regions of Ddo. The First regions analyzed was R4, in figure 6 are shown all possible 
epialleles of this region and their frequency at Stage E15. The results show that in the 
Region 4(that contains 6 CpGs) all possible theoretical epialleles ( Sixty-four (26)) are 
present. The distribution of epialleles is not predictable, indeed at this stage, the fully 
methylated profile is around 13% (the average methylation was evaluated at about 
56%), and the unmethylated molecules totaled about 10%, while the sum of 
intermediate epialleles is 77% but each of these is present in different percentage. The 
epialleles distributions among the mouse of the same stage and during the development 
are shown in figure 7. It’s possible to note how the patterns were extraordinarily 
conserved among mice of same developmental stages (All statistical correlation, 
Pearson correlation, are showed in Tab 2). Moreover, during the development (E15 to 
P30), the percentage of Fullymethylated and Unmethylated epiallele strongly change, 
and the intermediated epialleles show a main shift from profiles with more methylated 
CpG (Tetra/pentamethylated) to those with less methylated (mono/dimethylated) (Fig. 
6). The epiallele analysis was performed also for the other region of Ddo promoter and 
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for the minus strand of Region 4. The regions 1 to 3, as expected, don’t show a changed 
in epialleles frequency, while the regions 5 to 7 (Fig. 8C), indicate strong changes as 
the region 4, but I still study these changes. The exploration of the lower strand (R4) 
(Fig. 8A, 8B), confirm two things: 1) the epialleles trend among different 
developmental stages; 2) the equal frequency distribution among the mice of the same 
age (data not shown). In order to confirm that the observed epialleles distribution 
obtained from my results is not random, I used a simulated analysis of epialleles 
distribution starting from the values of methylation average of each CpG in the region 4 
(Fig. 9). As possible to understand from these results, the simulated epialleles 
distribution and the epialleles distribution of mice brain are strongly different. These 
results may indicate that the generation of methylation profiles is not random but it 
follows a precise scheme of formation and maintenance of DNA methylation. 
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Figure 5. Quantitative methylation analysis of a 3 kb genomic region of Ddo gene. A) Structure of the 
putative mouse Ddo gene promoter. Blue arrow indicates the transcription start site (+1). White box 
represents the putative regulatory upstream region. Black box represents exon 1. Gray box represents 
first intron. Positions of CpG sites are indicated as relative to TSS. The analyzed 3 kb genomic portion is 
divided in 7 regions (R1-R2-R3-R4-R5-R6-R7) corresponding to different amplicons. B) Graph 
represents methylation average at each CpG site analyzed by Illumina MiSeq Sequencer. Each color line 
represents the average of 3 mice at a given developmental stage. Blue = E15; red = P0; green = P30. 
Error bars show standard deviations. For each CpG site, the points labeled with different letters on top 
are significantly different (P < 0.05) based on post-hoc ANOVA analysis (Tukey test, performed on each 
CpG site). Where two developmental times were considered, Student t test was applied with*P < 0.05, 
**P < 0.01, ***P < 0.001. (From Florio et al 2017 Ref. 94) 
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Figure 6. All possible methyl CpG combinations (epialleles) at the Ddo R4 region. A) Representation of 
all 64 theoretically possible epialleles at region R4 of Ddo promoter containing 6 CpG sites. Circles 
represent the CpG sites analyzed (-363, -330, -318, -242, -175, and -125); black circles = methylated 
CpG; white circles = unmethylated CpG. B) Percent frequency of each epiallele in whole brain from 3 
mice (M1, M2, and M3) at E15 stage. (From Florio et al 2017 Ref. 94) 
 
30 
 
 
Figure 7. Epialleles frequency distribution at Ddo R4 region during different stages of mouse 
development (E15, P0, P14, P30). The pie charts represent the percentage of unmethylated epialleles (U 
= white), fully methylated epialleles (F = black), and all 62 intermediate epialleles (I = gray gradient). 
The line graph shows the percentage of each of the intermediate epialleles; each color line identifies one 
mouse. Blue = mouse 1; red = mouse 2, green = mouse 3. At the bottom of the last graph, the specific 
methyl CpG combinations of the 62 intermediate epialleles are reported. 1M identifies the group of 
monomethylated molecules; 2M = dimethylated; 3M = trimethylated; 4M = tetramethylated; 5M = 
pentamethylated epialleles. Pearson correlation R reported in Table 2. (From Florio et al 2017 Ref. 94) 
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Figure 8. A) Comparison between upper and lower strand methylation average of R4 DDO promoter 
region. B) DDO R4 Lower strand Epialleles distribution during four early stages of mouse 
development(E15-P0-P15-P30). C) Ddo promoter (R1-R2-R3-R5-R6-R7) epialleles evolution from P0 to 
P30 stages.The pie charts represent the percentage of unmethylated epialleles (U = white), fully 
methylated epialleles (F = black), and all intermediate epialleles (I = gray gradient). 
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Figure 9 Simulation approach showing how the observed epiallele frequency deviates from the random 
distribution. The results for three representative samples (whole brain at E15 developmental stage) are 
reported. Similar conclusions were reached also for all the other data points considered in this study (data 
not shown). A bootstrap/simulation approach was performed in the following way: to obtain a synthetic 
dataset of 10000 molecules, each containing 6 CpG sites, we first generated an array of 10000 x 6 cells 
filled with zeros. Then, to simulate stochastic methylation events, one cell was selected in an iterative 
and random manner by substituting its zero value with 1. The cycle was stopped when the global 
methylation probability (57% in the case of E15 whole brain) from the observed data was reached. This 
procedure was repeated three times in order to mirror the three mice used in the study. Briefly, the same 
methylation probability was assumed for all CpG sites (1/n, where n is the number of CpG sites). The 
frequency of each simulated epiallele was averaged and compared it with the real observed frequency. 
The results are shown in the barplot. On x-axis the epialleles and on y- axis their frequencies are 
reported, respectively. Red bars: real epiallele frequency; green bars: simulated epiallele frequency. The 
error bar of each observed epiallele in no case intersects with that of the corresponding simulation, 
indicating that the experimentally observed epiallele distribution was not random. (From Florio et al 
2017 Ref. 94) 
Table 2. 
Pearson correlation test of epialleles distribution Ddo R4 region 
STAGE Mice Pearson R p-value 
E15 M1/M2 0,986067197 1,89637E-48 
E15 M1/M3 0,992391755 2,71669E-56 
E15 M2/M3 0,9868598 3,30893E-49 
P0 M1/M2 0,959438583 1,08587E-34 
P0 M1/M3 0,944346038 1,15656E-30 
P0 M2/M3 0,88145423 3,27535E-21 
P14 M1/M2 0,786309702 3,66001E-14 
P14 M1/M3 0,846990179 4,13024E-18 
P14 M2/M3 0,981271547 1,26582E-44 
P30 M1/M2 0,833321788 4,37257E-17 
P30 M1/M3 0,801413887 5,13155E-15 
P30 M2/M3 0,984769846 2,69114E-47 
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4.4 The epialleles configuration of brain areas. 
 
To better understand if the epialleles distribution of whole mouse brain is equal in all 
brain areas or if there is a specific distribution for each of these, I performed the 
epialleles analysis of Ddo promoter Region 4, in five different brain areas 
(hippocampus HIPP, cortex CX, prefrontal cortex PFC, cerebellum CB, and striatum 
ST)at P30 age. Before this, I have assessed the methylation average of each area and 
then of all single CpGs (Fig. 10A and 10B). Three areas (CX, PFC, CB) seem to have a 
similar value, while the Hippocampus area and Striatum area show respectively 
low(15%) and high levels(50%) of DNA methylation. For what concern the epiallele 
analysis (Fig. 10C), first of all, is possible to note the different percentage of 
unmethylated and fullymethylated epialleles among different areas (Fig. 10C). 
Especially the striatum shows no more than 30% fullymethylated epiallele compared to 
the methylation average of 50% of this area. In the same way, the percentage of 
fullymethylated epiallele in the Hippocampus area is around 2%, while the methylation 
average is around 18%. Moreover, the intermediate epialleles distribution is highly 
heterogeneity among the brain areas. Notably, the difference among the areas often fall 
on the same methylation profiles, that are always present in each area but with different 
percentage (see peaks in the Fig. 10C.). 
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Figure 10. Epialleles composition analysis of Ddo R4 in separated areas of mouse brain (Hipp: 
hippocampus; CB: cerebellum; CX: Cortex; ST: striatum; PFC: prefrontal cortex) and in whole brain 
(WB) at P30 stage. A) Average methylation at the Ddo R4 region in each separated brain area. The bars 
labeled with different letters on top are significantly different based on post-hoc ANOVA statistical 
analysis (Tukey test). B) Average methylation at each CpG site (-363, -330, -318, -242, -175, and -125). 
The bars labeled with different letters on top are significantly different based on post-hoc ANOVA 
analysis (Tukey test) performed for each CpG site. C) Ddo R4 region epiallele frequency distribution. 
The pie charts represent the percentage of unmethylated epialleles (U = white); fully methylated 
epialleles (F = black); and all 62 intermediate epialleles (I = gray gradient). Each color line represents the 
distribution of 62 intermediate epialleles in one brain area, as indicated. At the bottom of the graph, the 
specific methyl CpG combinations of each of the 62 intermediate epialleles are reported. A P-value < 
0.05 was considered statistically significant. (From Florio et al 2017 Ref. 94) 
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4.5 Neural cells population analysis reveals a specific epialleles distribution. 
 
Once analyzed the epialleles frequencies in mouse whole, noted that there is a different 
distribution among the brain areas, I decided to investigate the methylation status of 
neuronal cells to understand if the high degree of epipolymorphism of brain tissue may 
be explained by the cellular heterogeneity. To do this, I analyzed four diverse neuronal 
cells population: neurons, oligodendrocytes, astrocytes, and microglial The first step 
was to investigate the average of methylation of the region 4 of Ddo promoter in these 
cells. As shown in Figure 11A the average of methylation isn't too far among 
populations, except for astrocytes cells that exhibit a much lower percentage. The 
microglial seems to have slightly higher levels of methylation than other cells. Then I 
performed an epialleles analysis (Fig. 11B), and the results indicate that the population 
with a low level of methylation (astrocytes) shows a high presence of unmethylated, 
monomethylated and dimethylated epialleles; while the higher methylated population 
shows an high frequency of tetramethylated and pentamethylated epialleles. One more 
time, as in the whole brain and in brain areas samples, the differences among the cell 
population always are due to the same CpG combinations. In particular, there are some 
epialleles that are constantly present, and they born from specific CpGs: -363, -330, -
242. These sites seem to be more susceptible to methylation processes, conversely the 
sites -175 and -125 appear to be more resistant to the methylation event. All the results 
derived from brain tissue and from neuronal cells suggest that there is a scheme in 
which a specific chain command indicate the cytosine able (or not) to undergo a 
methylation processes. In summary, we confirmed that most of the methylation rules 
observed in brain tissues are applied also for isolated brain cells, including the high 
percentage of intermediate epialleles, high degree of epipolymorphism, and high 
conservation of epialleles frequency among the same type of cells among individuals. 
These important rules seem to highlight that the methylation processes could be 
happened in a deterministic way rather than in a stochastic manner. 
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Figure 11. Averaged and single molecule methylation analysis of the Ddo promoter region in isolated 
primary brain cells A) Average methylation in different indicated brain cells. The bars labeled with 
different letters on top are significantly different based on post-hoc ANOVA statistical analysis 
(Tukey test). B) Frequency distribution of intermediate epialleles in primary cells. Neuro: primary 
neurons, blue bars in A and blue lines in B. Oligo: primary oligodendrocytes, red bars in A and red lines 
in B. Micro: primary microglial cells, green bars in A and green lines in B. Astro: primary astrocytes 
cells, violet bars in A and violet lines in B. in A (bars) and C (lines). The pie charts represent the 
percentage of unmethylated epialleles (U = white); fully methylated epialleles (F = black); and all 62 
intermediate epialleles (I = gray gradient). At the bottom of each graph, the specific methyl CpG 
combinations of each of the 62 intermediate epialleles are reported. (adapted from Florio et al 2017 Ref. 
94) 
 
 
4.6 Clonal feature of immortalized cell line 
 
Given the previous results, I wanted to understand if the same epialleles configuration 
studied in neuron and glia cells may be kept in an immortalized neuronal cell line. For 
this reason, I performed the methylation analysis using two different plates of A1 
cells(c-myc immortalized neurons). In figure 12A it is possible to see that the 
methylation average of these two cell plates as well as being similar to each other, is 
also similar to the primary neuron cell line (compare to figure 11B). This result lets 
believe that the epialleles frequencies could be similar, but unexpectedly the A1 cells 
shown a completely random distribution (Fig. 12B.) with an enrichment of few 
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epialleles and the total absence of others. Moreover, the configuration of methylation 
profiles is absolutely discordant between the two plates of immortalized neuron 
(Pearson R = 0.083). The lowest degree of epipolymorphism suggests that the 
immortalized neuron may be able to acquire a kind of clonal-like behavior, probably 
influenced by stochastic events. 
 
 
Figure 12. Averaged and single molecule methylation analysis of the Ddo promoter region in cultured c-
myc immortalized neurons. A) Average methylation. B) Epiallele distribution in c-myc cultured 
immortalized neurons. Neu C-Myc I and Neu C-Myc II: A1 C-Myc immortalized neurons, dark blue and 
orange, respectively, in A (bars) and B(lines). The pie charts represent the percentage of unmethylated 
epialleles (U = white); fully methylated epialleles (F = black); and all 62 intermediate 
epialleles (I = gray gradient). At the bottom of the graph, the specific methyl CpG combinations of each 
of the 62 intermediate epialleles are reported. (Adapted from Florio et al 2017 Ref. 94) 
 
 
4.7 From embryonic stem cells to neural cells 
 
Which is the origin of frequently methylation profiles that are present in all different 
neural cell populations? To answer this question, I evaluated the epialleles distribution 
of Ddo region 4 in a model of neural cells differentiation derived from stem cells (ESCs 
). This is one of the most surprising results, indeed, despite the similar methylation 
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average of these CpGs (Fig. 13A and 13B), the epialleles frequency shows a different 
configuration in these two kinds of cells (Fig. 13C). At the step of Embryonal stem cell, 
the distribution appears like a random way, where only the monomethyl epialleles seem 
to be slightly high. On the other hand, when the ESCs differentiate, appears a specific 
reorganization of each epiallele; it seem that during differentiation process, from a 
random state, the cells pass through a tidy state (Fig. 13D). One more time there is a 
prevalence of few peaks against others; indeed during differentiation, the epialleles that 
contain a -242 and/or -125 (and their derivate) decreases, conversely the epialleles 
derivate from -330 and -363 undergo a substantial increase. These results even more in 
a clear manner, suggest that behind the methylation or demethylation processes there is 
a precise deterministic mechanism that decides the destiny of each single CpG. 
Additionally, the epialleles distribution of differentiated stem cells strongly looks like a 
neuron or glial epialleles distribution; the peaks that rise in a chart (Fig. 13D) match to 
the majors seven epialleles detected in developing whole brain as well as neurons and 
glial cells, with different relative abundance. These seven epialleles are: -330; -363; -
330/-318; -363/-330; -363/-330/-318; 363/-330/-318/-242, 363/-330/-318/-242/-175. As 
possible to note, there is a strong presence of -330 and -363 CpGs, that influences the 
idea of the existence of methylated sites that are better able to guide the methylation 
process of near CpGs. For this reason, the figure 14A shows the heat maps of each CpG 
contribution to form all epiallele kind in four cell population (ESC, nESC, neuron, 
astrocyte). It is easy to note how the heat maps of ESC is significantly different from 
other populations, while the latter three are very similar to each other. 
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Figure 13. Single molecule methylation analysis in ESC neural differentiation model. A) Averaged methylation at 
Ddo R4 region in undifferentiated ESCs (U-ES) and in differentiated ESCs (nD-ES) from 3 independent 
experiments. B) Averaged methylation of each CpG site (-363, -330, -318, -242, -175, and -125) at Ddo R4 region 
(data are showed as mean +/-standard deviation; **P < 0.01). C) Microscope images of ESCs in undifferentiated 
state (U-ES) and upon differentiation toward neuronal phenotype (nD-ES). Bar =200 mm. Epiallele frequency 
distribution in 3 independent ESCs differentiation experiments (I, II, and III). The pie charts represent the relative 
percentage of fully unmethylated epialleles (U = white), fully methylated epialleles (M = black), and the 62 
intermediate epialleles (I = gray gradient). The line plots represent the frequency distribution of each of the 62 
intermediate epialleles (blue: undifferentiated ESC; red: differentiated ESCs). D) Comparison between average 
frequency distribution of each of the 62 Ddo intermediate epialleles, from 3 independent experiments, in 
undifferentiated (blue line) vs. differentiated (red line) ESCs. The specific methyl CpG combinations of each of the 
62 intermediate epialleles are indicated on the x-axis. 
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4.8 Principal Component Analysis of neural cell and ESC 
 
Another interesting point regard a post-hoc analysis based on epialleles frequency of all 
single cell population. Using a Principal Component analysis, I tried to perform an 
epigenetic correlation among all kind of neural cells analyzed in this work. The 
correlation was established on the abundance of each epiallele in each cell line. In 
figure 14B there are two graphs in which there is respectively the location of each cell 
population and of each epiallele. In the first graph it is important to note how the 
embryonal stem cells are located almost equidistant from the other population. 
Conversely, the neural population differentiated from ESC is positioned closely to 
neuron and astrocyte cells. In the second graph it should be noted the influence of 
monomethyl epiallele containing the CpG -363 and -330 [5,6] that are displayed in the 
same part where are located astrocyte, neuron and n-ES cells, to remark the importance 
of these CpG in these cells; while the monomethyl epialleles that contain the CpG -242, 
-175 and -125 [1,2,3] are much closer to ESC. Therefore it seems more truthful the 
assumption that in undifferentiated cells the methylation events occur randomly, while 
in differentiated cells the methylation /demethylation processes may follow a precise 
schedule, where the methylated state of more susceptible sites increases the likelihood 
that adjacent resistant sites become methylated. 
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Figure 14 A) The heatmaps show the contribution of each CpG in different epiallelic classes among 4 
cell types (U-ES = undifferentiated ESC; nD_ES = neuronal differentiated ESCs). The color scale from 
red to yellow (from low to high values) shows the contribution of each CpG to formation of 
monomethylated (1M), dimethylated (2M), trimethylated (3M), tetramethylated (4M), pentamethylated 
(5M), and fully methylated (6M) molecules, respectively. B) Epigenetic correlation of Ddo R4 epialleles 
distribution in ES and different purified brain-derived cell types performed by PCA. Scores plot 
represents the distribution of each specific cell type (blue = neurons; pink = oligodendrocytes; green = 
microglial; violet = astrocytes; gray = U-ES undifferentiated ESCs, red = nD-ES differentiated ESCs). 
The analysis was based on the qualitative and quantitative influence of each of the 64 epialleles displayed 
by each cell type. In the Loading plots of PCA the vectors represented by red arrows show how (the 
direction) and how much (the length) each epiallelic profile contributes to the individual correlations 
represented by PC1 and PC2. Note that each epiallele is named with numbers (1–62) or letters (U, F), as 
reported in Fig. 6 
 
 
4.9 Dynamic evolution of DDO lower strand epialleles during neural differentiation. 
As above showed, the epialleles distribution between upper and lower strand of DDO 
promoter region follows the same demethylation process during the early stages of 
mouse development. For this reason, I decided to investigate the methylation status of 
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DNA lower strand during neural differentiation starting from ES cells (day 0) and 
passing through the days 2, 4, 8, up to day 14 of differentiation (mature neuron). As 
shown in figure 15, during the neural maturation the methylation average undergoes a 
significant increase until day 8 then sugnificantly decreased, returning at final stages 
(day 14) to a similar percentage of day 0. These results are in agreement with data 
previously shown about the methylation of DDO Upper strand in stem cells. The 
evolution of epiallele distribution during these differentiation events follows a specific 
dynamic that it was unexpected. Indeed, the epialleles conformation at embryo stem 
cell level (day 0) (Fig.16) seems to be equally distributed with two major peaks: the 
fully un-methylated and fully methylated profiles. Instead, at days 2 and 4 it was 
possible to appreciate a strong shift toward the penta-methylated and fully methylated 
profiles (Fig. 17 A and B), where especially the fully methylated profile reaches a 50% 
at day 4. Surprisingly, between day 8 (Fig. 18) and 14 (Fig. 19) the epialleles frequency 
distribution underwent a significant variation, since the number of more methylated 
epialleles strongly decreased while the fully unmethylated profile peaked up to 20%. 
During these changes, the intermediate epialleles were shaped in an ordered manner 
and showed a distribution strongly resembling the adult mouse brain profiles. To better 
understand if there is a specific correlation between epialleles distribution and each 
stage of neural differentiation, I performed a “betadiversity” analysis. In figure 20 the 
PCoA plot represents the beta diversity and shows a specific epialleles assortment in 
each group, where each differentiated stage cluster away from others. These results 
suggest the existence of a well orchestrated mechanism that generates and dynamically 
modulates the frequency of each epiallele during the neural differentiation from day 0 
to day 14. 
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Figure 15. The methylation average of DDO R4 lower strand during the neural differentiation from 
embryo stage (day 0) to day 14. Each bar represents one stage of differentiation.   
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Figure 16. The epialleles distribution of DDO R4 lower strand at embryo stage (day 0). On the x axis is 
report the seven epialleles classes: un-methylated and mono-methylated (green), di-methylated, tri-
methylated and tetra-methylated (orange), penta-methylated and fully methylated (red). The y-axis 
represents the percentage of each epiallele at this stage of differentiation.   
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A 
 
B 
 
Figure 17. The epialleles distribution of DDO R4 lower strand at day 2 of neural differentiation (A) and 
at day 4 (B). On the x axis is report the seven epialleles classes: un-methylated and mono-methylated 
(green), di-methylated, tri-methylated and tetra-methylated (orange), penta-methylated and fully 
methylated (red). The y-axis represents the percentage of each epiallele at this stage of differentiation.   
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Figure 18. The epialleles distribution of DDO R4 lower strand at day 8 of neural differentiation. On the 
x axis is report the seven epialleles classes: un-methylated and mono-methylated (green), di-methylated, 
tri-methylated and tetra-methylated (orange), penta-methylated and fully methylated (red). The y-axis 
represents the percentage of each epiallele at this stage of differentiation.   
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Figure 19. The epialleles distribution of DDO R4 lower strand at day 14 of neural differentiation. On the 
x axis is report the seven epialleles classes: un-methylated and mono-methylated (green), di-methylated, 
tri-methylated and tetra-methylated (orange), penta-methylated and fully methylated (red). The y-axis 
represents the percentage of each epiallele at this stage of differentiation.   
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The beta diversity analysis of DDO R4 Lower strand during neural 
differentiation 
 
Figure 20. The PCoA plot of beta-diversity analisys performed on DDO R4 lower strand epialleles 
distribution during the neural differentiation from ES cells. The colored circles represent each stage of 
neural differentiation ( red = day 0, orange = day 2, green = day 4, violet = day 8 and blue = day 14). The 
gray circiles represent the 64 possible epialleles, The dimension of gray circles represents the abundance 
of each epiallele. 
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4.10 Dynamic evolution of Nanog, BDNF, tubulin III and GFAP expression and 
methylation during neural differentiation. 
 
I sought to determine the variation of DNA methylation profiles of genes involved in 
neural and glial differentiation to check whether they are affected by changes similar to 
the above considered reference gene. In most of cases I found that methylation profiles 
(Fig. 21) changed consistently and inversely correlating with the expression profiles 
(not shown) making these genes additional and functionally appropriate ideal models to 
study the role of epiallele distribution variation during differentiation. Indeed, ongoing 
chromatin immunoprecipitation experiments in my lab are trying to elucidate the 
factors involved and the mechanisms underlying the changes in epiallele distribution 
during differentiation and to study independently the methylation and demethylation 
processes. Finally, about the general meaning of the epiallele distribution during 
differentiation and development, in our lab we are currently trying to translate these 
findings to human brain and brain cells in order to check whether anomalies in 
epialleles profiles generation and maintenance may be associated with neuropsychiatric 
conditions. 
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Figure 21. The methylation average of genes implicated in neural differentiation (Nanog, BDNFIV 
Upper and lower strand, Tubuline III and GFAP. The methylation average is evaluated during neural 
differentiation from embryo stage (day 0) to day 14. Each bar represents one stage of differentiation (day 
0, day 2, day 4, day 8, day 14).   
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DISCUSSION 
 
5.1  
 
Several studies addressing DNA methylation patterns at genomic level in health and 
disease, have successfully identified tissue- or disease-specific DNA methylation 
patterns and differentially methylated regions during normal development or in 
diseased states (28-30, 48, 68, 69, 71, 87). However, the great majority of these studies, 
even when performed at high resolution, could measure the average CpG methylation at 
each locus while the processes driving methylation establishment and changes are still 
poorly understood. In this study, I have performed an ultra-deep methylation analysis to 
study the methylation profiles of single genomic regions (surrounding Ddo gene) taking 
into account the cell to cell heterogeneity and quantifying the frequency of each 
methylation pattern (epiallele) present in mixed and pure populations of brain cells 
during development and neural differentiation. The results substantiate well appreciated 
general phenomena including: i) high degree of epipolymorphism is detected either in 
whole brain, in brain areas and in isolated brain cells, being virtually all combinations 
of methylated CpGs represented at variable frequency; ii) the majority of epialleles 
were neither fully methylated or fully protected in all the analyzed systems; iii) the 
relative epiallele frequency distribution changed during development, it was different 
among individual brain areas, as well as in different purified brain derived cells, but 
profiles were always strikingly conserved among individual developmental stages, 
brain areas or primary cell types derived from different mice; iv) cultured neurons 
transformed by c-myc showed lower degree of epipolymorphism and stochastic 
epiallele enrichment showing profiles strongly divergent among different cell plates 
and passages; v) an epigenetic drift at Ddo gene, clearly appreciated in term of epiallele 
profiles and fully unpredictable by conventional methylation determination, marked ES 
cells neural differentiation process. Overall, the finding of strong conservation in the 
epigenetic diversity and epialleles frequency distribution, also in purified cells, supports 
the possible existence of mechanisms oriented to maintain the epigenetic system in a 
dynamic stability, where the methylation state of each CpG in single cells is not stable 
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rather it is subject to periodic fluctuations. In particular, results obtained by 
differentiating ESC suggest that in the undifferentiated state the different CpG sites are 
methylated independently and stochastically while a well-orchestrated interplay 
between contiguous CpGs differing in methylation susceptibility underlies specific 
epiallele frequency and dynamics in differentiated state. This appears to occur in a 
spatial-specific manner where the methylated state of more susceptible sites (e.g. -330 
and -363 in the R4 region) favour methylation of adjacent otherwise partially resistant 
sites. These rules are retained in mature brain where the differential average 
methylation in each cell type mainly derives by the relative percentage of fully 
methylated and unmethylated molecules and by the relative abundance of specific 
peaks, (including mono-, di- tri-, tetra- and penta-methylated molecules, respectively) 
within a prevalent fixed set of intermediate epialleles. Whether these rules may apply to 
different genomic regions, are limited to some specific regions (e.g. CpG poor 
promoter) or are a peculiarity of Ddo promoter, remains to be determined. However, I 
believe that my data represent a solid proof of concept that epialleles analysis, possibly 
implemented by studies on set of genes, and using mutant mice and disease-model, may 
reveal unprecedented mechanism underlying DNA methylation establishment, 
dynamics and alteration within tissue cell populations. The present study clearly 
demonstrates the importance of single molecule methylation analysis in mixed, as well 
in pure, cell populations and points on the informativeness of epiallele frequency 
distribution analysis, to be eventually associated to evaluation of average methylation, 
in order to get insight into the origin of methylation heterogeneity and, possibly in the 
near future, its functional relevance. Although the limit of this approach is that it does 
not allow one to directly match cell by cell methylation, mRNA expression and cell 
identity data, this approach may circumvent the difficulties and the high costs of the 
single-cell analysis with which it shares the ability to investigate in detail cell to cell 
methylation differences in a cell population. We have recently developed a pipeline, 
namely amplimethprophiler (https://sourceforge.net/projects/amplimethprofiler), that 
render such kind of analysis, performed at individual genomic loci, easily approachable 
by other researchers interested to apply these principles to any biological system and 
genomic regions. At our knowledge, nowadays no studies have addressed the epialleles 
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diversity in brain and in brain-derived cells. In the recent past, very few studies 
ingeniously addressed the cell to cell methylation heterogeneity, prevalently in tumor 
systems and at genome-wide level (74, 75, 88-91), supporting general rules that are 
mostly consistent with the here presented data. Landan and colleagues (75) suggested 
that a stochastic series of subtle and progressive methylation changes in cancer 
evolution leads to deterministic methylation profiles. A spatially specific methylation 
patterns emerged, by means that some CpGs are particularly sensitive to changes in 
methylation creating an initiation point for methylation that then spreads over the 
region. Our data are compatible with this model according which in subsets of cells 
within each population, methylation profiles take origin by the spreading from 
susceptible sites that when methylated become able to influence nearby CpGs. 
Moreover, by the reanalysis of RRBS data from normal and cancerous tissues, Landan 
et al. (75) also observed that two methylation patterns of DNA molecules from the 
same cell population are rather different each with other with exception of H1 ESC and 
testis which displayed coherent and homogeneous methylation profiles. By contrast, in 
developing brain and purified brain cells we found a striking conservation of epiallele 
profiles at Ddo gene within the same type of samples deriving from different mice. 
Moreover, we found that in undifferentiated ES cells the methylation profiles were 
rather disorganized and highly polymorphic at Ddo gene shifting toward an ordered, 
non-stochastic and less polymorphic epiallele profile upon induction of neural 
differentiation. These apparent discrepancies may derive by the fact that our analysis 
was based on a much higher number of reads per locus and that it was performed on 
CpG poor gene regulatory region that may behave in a different and more specific 
manner compared to CpG rich regions which are mostly considered, especially in 
RRBS-based analyses, by genome wide approaches. Indeed it has been demonstrated 
that in physiological conditions CpG poor promoters are subjected to a much finer 
methylation-dependent control compared to dense CpG regions (7, 92). In a recent 
study, Li et al. (74), using the methclone program, were able to map a series of loci 
(eloci), consisting in 4 adjacent CpGs, subjected to epigenetic drift during leukemia 
progression. This study, based on combinatorial entropy as a measure of epialleles shift 
observed at single loci throughout the genome, revealed enrichment of eloci in the 
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genic region, in particular at promoter regions, which is in line with my findings. 
Moreover, by the analysis of eloci during leukemia progression, the authors concluded 
that the analysis of epiallele composition may reveal clonal shifts at specific loci 
otherwise not detectable. In agreement with this observation, I found that, upon 
differentiation of ES cells, Ddo promoter underwent a methylation shift, as clearly 
detected by epiallele analysis, which was unpredictable by traditional methylation 
analysis. However, previous studies addressing epialleles composition were mostly 
performed in tumor progression systems, and thus epialleles changes were interpreted 
as clonal shifts. It would be very interesting in the future to establish whether the 
epigenetic drift, here reported at Ddo gene during differentiation, is due to a clonal 
effect or, rather and more likely, to a methylation remodelling occurring in ES cell 
population upon induction to differentiate.  
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CONCLUSION 
6.1 
 
My studies highlight how the new way (epialleles analysis) to study the DNA 
methylation may reveal some changes in methylation status of certain genes difficult to 
find by classical approach. Leveraging an ultra-deep sequencing method, the epialleles 
analysis, allowed me to better characterize the methylation status of Ddo promoter 
during the mouse brain development and in neural differentiation starting from 
embryonic stem cell. The obtained results show that in brain tissue there is a high 
polymorphic methylation that may undergo to a constant turnover. Moreover, the 
extraordinary degree of conservation among mice with the same stage of development, 
among the same types of cell populations indicate that the generation of methylation 
profiles seems to be dictated by an accurate mechanism governed by a deterministic 
principle. These rules, may not be valid in immortal cells (like tumoral cells), where the 
apparent clonal behavior does underpin possible stochastic influences. In addition, the 
epigenetic drift that occur during neuronal differentiation from stem cells, visible only 
using epialleles technique, strengthens the hypothesis that there are unambiguous 
methylation mechanisms underlying neuronal development. Moreover, my results 
evidenced a pyramidal epiallele hierarchy. In a few words, if one CpG is methylated 
there is a higher probability that the adjacent CpG will be methylated. Overall, given 
that my findings indicate that epialleles composition dynamics in brain cell population 
is very finely tuned and strikingly conserved, I conclude that tracking epiallele profiles 
may help “to identify barcodes” to get insight into mechanisms underlying DNA 
methylation establishment, changes and, potentially, alterations of these processes in 
neurodevelopmental diseases that may be not revealed by conventional, either gene 
specific or genome-wide, averaged methylation analyses. 
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